Publications by authors named "Corey Lipchik"

Claim this Profile
E
Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Lujia Chen, Ying Wang, Chunhui Cai, Ying Ding, Rim S Kim, Corey Lipchik

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.
Tanner J Freeman, Thomas J George, Samuel A Jacobs, Greg Yothers, Tatjana Kolevska, Corey Lipchik

Cancer Chemother Pharmacol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Lujia Chen, Ying Wang, Chunhui Cai, Ying Ding, Rim S Kim, Corey Lipchik

J Clin Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero, Corey Lipchik

Breast Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero, Corey Lipchik

Breast Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial.
Pooja P Advani, Kathryn J Ruddy, Joerg Herrmann, Jordan C Ray, Emily C Craver, Corey Lipchik

Front Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab.
Lawrence D Wagman, David A Geller, Samuel A Jacobs, Nicholas J Petrelli, Carmen J Allegra, Corey Lipchik

J Surg Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib-Plus-Cetuximab in Quadruple-WT () Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.
Samuel A Jacobs, James J Lee, Thomas J George, James L Wade, Philip J Stella, Corey Lipchik

Clin Cancer Res· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Samuel A Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, Corey Lipchik

Breast Cancer Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 breast cancer.
Samuel A Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, Corey Lipchik

Breast Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.
Patrick G Gavin, Nan Song, S Rim Kim, Corey Lipchik, Nicole L Johnson

JAMA Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
Nan Song, Katherine L Pogue-Geile, Patrick G Gavin, Greg Yothers, S Rim Kim, Corey Lipchik

JAMA Oncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.
Kay Pogue-Geile, Greg Yothers, Yusuke Taniyama, Noriko Tanaka, Patrick Gavin, Corey Lipchik

J Natl Cancer Inst· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
Patrick G Gavin, Linda H Colangelo, Debora Fumagalli, Noriko Tanaka, Matthew Y Remillard, Corey Lipchik

Clin Cancer Res· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis